Skip to Main Content

SAN FRANCISCO — When researchers recently showed in a clinical trial that a drug held some promise as a multiple sclerosis treatment, they might have expected interest from biopharma companies fishing for the next addition to their pipelines.

They heard crickets.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!